Mereo BioPharma Group plc

NASDAQ:MREO

Biotechnology

Healthcare
$0.32 +9.69%

+$0.03 today

Market cap
$51.08M
Beta
0.28
P/E (TTM)
-1.4
EPS (TTM)
-$0.22
52W Low $0.20High $3.05

Volume 1.26M

Average 3.36M

MREO Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Mereo BioPharma Group plcNASDAQ: MREO

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development growth accelerates

Q1 FY2026 research & development of $4.74M rose 20.6% year over year, ahead of the -12.8% change in trailing-twelve-month research & development. Sequentially, it rose 13.0% from the prior quarter. Over 3 fiscal years it compounded at -16.7% a year.

Context

  • Research & development amounted to 3553.2% of revenue in FY2025.
  • Research & development increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +20.6% holds above the trailing-twelve-month pace of -12.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$4.74M+13.0% QoQ
Last fiscal yearDec 2025
$17.77M-15.1% YoY
LTMMar 2026
$18.13M-12.8% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+20.6%——
1 year-15.1%——
3-year CAGR-16.7%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
17.77M USD
Year-over-year change
-15.1%
4-year CAGR
-13.5%

Research & Development vs competitors

How MREO compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -12.8% is the 7th highest of 10, against a peer median of +11.3%.
  • Research & development amounts to 3625.8% of revenue for MREO, versus a peer median of 1313.6%.
MREO Competitors
Research & Development for MREO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
KYTXKyverna Therapeutics, Inc.LTM Mar 2026$126.01M USD-0.7%+67.6%—
CAPRCapricor Therapeutics, Inc.LTM Mar 2026$92.92M USD+60.8%+57.0%—
LXEOLexeo Therapeutics, Inc. Common StockLTM Mar 2026$62.33M USD-17.5%+9.1%—
SLNSilence Therapeutics plcLTM Mar 2026$61.84M USD—+24.0%6710.8%
IMMPImmutep LimitedFY2025A$61.41M AUD+47.8%+25.1%1217.6%
ACIUAC Immune S.A.LTM Mar 2026CHF 52.18M CHF-17.6%-2.2%1409.6%
CTNMContineum Therapeutics, Inc. Class A Common StockLTM Mar 2026$49.38M USD+11.3%+45.0%—
PRQRProQR Therapeutics N.V.LTM Mar 2026€44.34M EUR+12.6%-7.1%329.9%
CADLCandel Therapeutics, Inc.LTM Mar 2026$36.32M USD+88.9%+13.6%—
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$20.65M USD-58.3%-18.4%—
MREOMereo BioPharma Group plcLTM Mar 2026$18.13M USD-12.8%-16.7%3625.8%
Peer median (excluding MREO) —+11.3%+18.8%1313.6%

Competitors are the stored peer set for MREO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue49.21M010M0500K
Cost of Revenue24.17M(257.44K)2.57M1.09M133K
Gross Profit25.04M257.44K7.43M(1.09M)367K
Gross Margin50.9%—74.3%—73.4%
Research & Development31.8M30.75M17.42M20.93M17.77M
Selling, General & Admin21.5M23.18M18.42M26.43M23.01M
Operating Expenses53.3M53.92M35.84M47.36M38.62M
Depreciation & Amortization866.47K895.5K1.06M1.09M1.15M
EBITDA25.49M(39.98M)(26.06M)(40.8M)(40.47M)
EBITDA Margin51.8%—-260.6%—-8094.8%
Operating Income(28.26M)(53.67M)(28.42M)(47.36M)(38.26M)
Operating Margin-57.4%—-284.2%—-7651.4%
Interest Income1.38K696K2.13M3.04M2.17M
Interest Expense5.22M3.36M2.88M1.37M255K
Other Income / Expenses47.48M9.21M(1.58M)4.11M(3.62M)
Income Before Tax19.22M(44.46M)(30M)(43.25M)(41.88M)
Pre-Tax Margin39.1%—-300.0%—-8375.6%
Income Tax Expense2.05M(2.34M)(532K)00
Net Income17.17M(42.12M)(29.47M)(43.25M)(41.88M)
Net Margin34.9%—-294.7%—-8375.6%
EPS (Basic)749.65(1,750.35)(1,100.22)(0.29)(0.26)
EPS (Diluted)749.65(1,750.35)(1,100.22)(0.29)(0.26)
Weighted Avg Shares116.73M120.64M131.89M147.92M159.42M
Weighted Avg Shares (Diluted)116.73M120.64M131.89M147.92M159.42M

Mereo BioPharma Group plc

NASDAQ:MREO

Intrinsic Alpha fair value

Locked

Current Price

$0.32

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.